中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipeline
Overview
HCV
HBV
HIV
Partnership
Investors
Financials & Filing
Presentation Materials
News
2020
2019
2018
2017
2016
2015
2014
Careers
Investors
Financials & Filing
Presentation Materials
2020 Interim Report
2020-09-24
Voluntary Announcement - Gannex Filed IND in the U.S. for Its NASH Drug Candidate ASC42, an FXR Agonist
2020-09-14
Voluntary Announcement - Gannex and Galmed Expand Development Programs for NASH through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
2020-09-09
Voluntary Announcement - Proposed Share Repurchase under the Repurchase Mandate
2020-09-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2020
2020-09-04
2020 Interim Results
2020-08-28
Voluntary Announcement - Completion of Bridging Study of ASC18
2020-08-20
Voluntary Announcement - First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, A Subcutaneously Administered PD-L1 Antibody
2020-08-17
Notice of Board Meeting
2020-08-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2020
2020-08-05
1
2
3
4
»
